SYX-5219 / Sitryx - LARVOL DELTA

Sitryx initiates Phase 1 clinical trial of potential disease-modifying treatment for atopic dermatitis SYX-5219 (GlobeNewswire) - "Sitryx Therapeutics...today announces the initiation of its first-in-human Phase 1a clinical trial evaluating SYX-5219 for the treatment of atopic dermatitis....The Phase 1a trial, initiated in the UK, is an interventional placebo-controlled study designed to assess the safety, tolerability and pharmacokinetics of SYX-5219 in healthy volunteers. It is the first of a two-part study, with the Phase 1b trial in adults with moderate to severe atopic dermatitis expected to commence later in 2025 in the UK, Europe and the US."

Trial status • Atopic Dermatitis

Sitryx nominates SYX-5219 a novel, oral and targeted PKM2 activator for clinical development in atopic dermatitis (GlobeNewswire) - "Sitryx Therapeutics...has nominated SYX-5219 as the first candidate from its proprietary pipeline to progress to regulatory non-clinical studies to support a clinical trial authorization (CTA). SYX-5219 has the potential to address a broad range of inflammatory diseases and will advance into the clinic for the treatment of atopic dermatitis, the most common inflammatory skin disease....Regulatory submission preparation for SYX-5219 is underway, with clinical trials expected to commence in early 2025. SYX-5219 is expected to be the first program to enter clinical development from Sitryx’s proprietary pipeline of potential therapies that leverage metabolism to modulate immune cell function."

New molecule • New trial • Atopic Dermatitis • Dermatitis • Dermatology • Immunology